Scilex HoldingSCLX
About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Employees: 113
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
427% more call options, than puts
Call options by funds: $237K | Put options by funds: $45K
70% more capital invested
Capital invested by funds: $45.5M [Q1] → $77.2M (+$31.7M) [Q2]
4.88% more ownership
Funds ownership: 17.21% [Q1] → 22.08% (+4.88%) [Q2]
11% less funds holding
Funds holding: 100 [Q1] → 89 (-11) [Q2]
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 47% 1-year accuracy 114 / 245 met price target | 621%upside $7 | Buy Reiterated | 21 Oct 2024 |
Alliance Global Partners James Molloy 13% 1-year accuracy 1 / 8 met price target | 1,341%upside $14 | Buy Initiated | 16 Oct 2024 |
Financial journalist opinion
Based on 8 articles about SCLX published over the past 30 days